BGBIO.OL Live signals | Maximize Profits with Getagraph.com

BUY 1029 min ago

@ NOK0.159

Issued: 17 Apr 2024 @ 09:00

Return: 1.76%

Previous signal: Apr 17 - 07:54

Previous signal: Sell

Return: -0.99 %

Live Chart Being Loaded With Signals

Commentary (17 Apr 2024 @ 10:29):
Our systems believe the stock currently is overvalued by 0.22% compare to its pairs and should correct downwards.

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases...

Stats
Today's Volume	19.22M
Average Volume	45.72M
Market Cap	436.11M
EPS	NOK0 ( 2024-02-15 )
Next earnings date	( NOK-0.0200 ) 2024-05-23
Last Dividend	NOK0 ( N/A )
Next Dividend	NOK0 ( N/A )
P/E	-0.290
ATR14	NOK0.0100 (6.24%)

Correlation (AI algo v.1.1b): Overvalued: -0.22% NOK0.160 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: -0.21 (neutral)

Short: 0.00 (neutral)

Signal:(52) Neutral

BerGenBio ASA Correlation

10 Most Positive Correlations
PLT.OL	0.937
ELIMP.OL	0.935
KMCP.OL	0.931
TRVX.OL	0.925
ELABS.OL	0.908
ABG.OL	0.895
AKER.OL	0.893
VOW.OL	0.892
SADG.OL	0.891
EFUEL.OL	0.884

10 Most Negative Correlations
AYFIE.OL	-0.95
ATEA.OL	-0.929
TECH.OL	-0.886
ELK.OL	-0.885
BAKKA.OL	-0.882
BWO.OL	-0.877
PEXIP.OL	-0.871
BOUV.OL	-0.865
GOD.OL	-0.864
SMOP.OL	-0.862

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BerGenBio ASA Correlation - Currency/Commodity

0.00
( neutral )

BerGenBio ASA Financials

Annual	2022
Revenue:	NOK389 000
Gross Profit:	NOK389 000 (100.00 %)
EPS:	NOK-0.390

Q3	2023
Revenue:	NOK0
Gross Profit:	NOK-109 000 (0.00 %)
EPS:	NOK-0.0107

Q2	2023
Revenue:	NOK0
Gross Profit:	NOK-7 000.00 (0.00 %)
EPS:	NOK-0.150

Q1	2023
Revenue:	NOK0
Gross Profit:	NOK-7 000.00 (0.00 %)
EPS:	NOK-0.0926

Financial Reports:

No articles found.

BerGenBio ASA

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.